Dr. Oh on AR-Targeted Therapy and Chemotherapy for CRPC

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Patients who receive chemotherapy after AR-targeted therapy seem to see better results, states Oh. Initially, these patients were intrinsically sicker and had worse prognostic factors

The patients with the most systemic types of CRPC will not respond to a second AR-targeted therapy and will potentially see a survival benefit if they receive chemotherapy.